Research Article

Can neutrophil / lymphocyte ratio be used as a predictor of the hepatic fibrosis in chronic hepatitis B patients

Volume: 58 Number: 2 June 28, 2019
  • Sevil Özer Sarı *
  • Hüseyin Köseoğlu
  • Mustafa Akar
  • Tevfik Solakoğlu
  • Osman Ersoy
EN TR

Can neutrophil / lymphocyte ratio be used as a predictor of the hepatic fibrosis in chronic hepatitis B patients

Abstract

Aim: Assessing fibrosis in chronic hepatitis B (CHB) patients is important in preventing cirrhosis and hepatocellular cancer development. Liver biopsy is the golden standard in evaluating fibrosis. Because liver biopsy is invasive and has complications, non-invasive tests to demonstrate liver histopathology have become more important. There are some studies that demonstrate the relationship between neutrophil/lymphocyte ratio (NLR) and fibrosis in nonalcoholic steatohepatitis and CHB patients. The purpose of the present study was to evaluate the relationship between NLR and hepatic fibrosis in CHB patients. Materials and Methods: Sixty-seven patients who were under follow-up by our hepatology outpatient clinic and had liver biopsies were reviewed retrospectively. Demographics, laboratory parameters and values measured with liver biopsy were recorded for each patient. Results: The mean age of the study population was 48.6±11.7 years. Seventeen women (25.4%) and 50 men (69.6%) were included in the study. Fibrosis degree was 0 in 8 patients, 1 in 15, 2 in 8, 3 in 18, 4 in 7, 5 in 9, and 6 in 2. No significant relationship was found between fibrosis degree which was detected by liver biopsy and NLR in CHB patients (p=0.54). Conclusion: NLR ratio was not considered to be an effective parameter to demonstrate fibrosis in CHB patients.

Keywords

References

  1. Lok ASF, McMahon BJ. AASLD practice guideline: Chronic hepatitis B: Update of therapeutic guidelines. Rom J Gastroenterol 2004;13(2):150-4.
  2. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005;25(Suppl 1):3-8.
  3. Bravo A, Sheth SG, Chopra S. Liver biopsy. N Eng J Med 2001;344(7):495-500.
  4. Mardini H, Record C. Detection of assessment and monitoring of hepatic fibrosis: Biochemistry or biopsy? Ann Clin Biochem 2005;42(Pt 6):441-7.
  5. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68.276 biopsies. J Hepatol 1986;2(2):165-73.
  6. Lee IC, Huang YH, Chan CC. Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis B. Clin Nutr 2011;30(5):647-52.
  7. Ucar F, Sezer S, Ginis Z et al. APRI, the FIB-4 score, and Forns index have noninvasive diagnostic value for liver fibrosis in patient with chronic hepatitis B. Eur J Gastroenterol Hepatol 2013;25(9):1076-81.
  8. Martinez SM, Crespo G, Navasa M, Forns X. Noninvasive assesment of liver fibrosis. Hepatology 2011;53(1):325-35.

Details

Primary Language

Turkish

Subjects

Health Care Administration

Journal Section

Research Article

Authors

Sevil Özer Sarı *
0000-0001-8830-0371
Türkiye

Hüseyin Köseoğlu
0000-0002-2197-7473
Türkiye

Mustafa Akar
Türkiye

Tevfik Solakoğlu
0000-0002-5735-4200
Türkiye

Osman Ersoy
0000-0002-1364-5962
Türkiye

Publication Date

June 28, 2019

Submission Date

February 15, 2018

Acceptance Date

May 23, 2018

Published in Issue

Year 1970 Volume: 58 Number: 2

Vancouver
1.Sevil Özer Sarı, Hüseyin Köseoğlu, Mustafa Akar, Tevfik Solakoğlu, Osman Ersoy. Nötrofil / lenfosit oranı kronik hepatit B hastalarında karaciğer fibrozisini saptamada kullanılabilir mi? EJM. 2019 Jun. 1;58(2):136-9. doi:10.19161/etd.504466

Ege Journal of Medicine enables the sharing of articles according to the Attribution-Non-Commercial-Share Alike 4.0 International (CC BY-NC-SA 4.0) license.